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Perspectives on extended‑release naltrexone
induction among patients living with HIV
and opioid use disorder: a qualitative analysis
Kim A. Hoffman1* , Robin Baker1, Laura C. Fanucchi2, Paula J. Lum3, Lynn E. Kunkel4, Javier Ponce Terashima5,
Dennis McCarty3, Petra Jacobs6 and P. Todd Korthuis1,4

Abstract
Background: The CHOICES study randomized participants with HIV and opioid use disorder (OUD) to HIV clinicbased extended-release naltrexone (XR-NTX), which requires complete cessation of opioid use, versus treatment-asusual (i.e., buprenorphine, methadone). Study participants randomized to XR-NTX were interviewed to assess their
experiences with successful and unsuccessful XR-NTX induction.
Methods: Semi-structured qualitative interviews were completed with a convenience sample of study participants with HIV and OUD (n = 37) randomized to XR-NTX in five HIV clinics between 2018 and 2019. All participants
approached agreed to be interviewed. Interviews were digitally recorded, professionally transcribed, and analyzed
using thematic analysis.
Results: Participants included women (43%), African Americans (62%) and Hispanics (16%), between 27 to 69 years
of age. Individuals who completed XR-NTX induction (n = 20) reported experiencing (1) readiness for change, (2) a
supportive environment during withdrawal including comfort medications, and (3) caring interactions with staff. Four
contrasting themes emerged among participants (n = 17) who did not complete induction: (1) concern and anxiety about withdrawal including past negative experiences, (2) ambivalence about or reluctance to stop opioids, (3)
concerns about XR-NTX effects, and (4) preferences for other medications.
Conclusions: The results highlight opportunities to improve initiation of XR-NTX in high-need groups. Addressing
expectations regarding induction may enhance XR-NTX initiation rates.
Trial Registration ClinicalTrials.gov: NCT03275350. Registered September 7, 2017. https://clinicaltrials.gov/ct2/show/
NCT03275350?term=extended+release+naltrexone&cond=Opioid+Use.
Keywords: Extended-release naltrexone, Opioid withdrawal, Induction, Opioid use disorder, HIV
Background
Approximately 2 million individuals in the U.S. have an
opioid use disorder (OUD) [1] and only a fraction receive
medications for opioid use disorder (MOUD) treatment
*Correspondence: hoffmaki@ohsu.edu
1
Oregon Health and Science University-Portland State University School
of Public Health, Portland, OR, USA
Full list of author information is available at the end of the article

[2, 3]. Untreated OUD is associated with increased HIV
risk behaviors [4, 5], decreased receipt of antiretroviral
therapy (ART) [5–7], decreased ART adherence [5, 8–
10], and decreased HIV viral suppression [11, 12]. Treatment of OUD can increase engagement in HIV care and
enhance health outcomes [11, 13]. MOUD with an opioid
receptor agonist (methadone), partial agonist (buprenorphine), or opioid antagonist (extended-release naltrexone) effects at the opioid mu receptor facilitate recovery
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from OUDs [14]. Only 36% of specialty substance use
disorder treatment organizations in the U.S., however,
provide MOUD [15].
Despite compelling evidence that MOUD is effective
[15–19], these medications remain underutilized [20].
This is due in part to the need for daily dosing. Recent
advances are changing the landscape; some partial and
full antagonist treatments such as extended-release formulations of naltrexone (XR-NTX) and buprenorphine
provide alternatives to the daily dosing requirements of
methadone. XR-NTX, a deep muscle injection that lasts
28 days, eliminates the need for daily dosing. While longacting formulations may improve treatment adherence,
a recent study found that it was more difficult to initiate XR-NTX than buprenorphine in patients with OUD
[19]; the process of initiating XR-NTX so that someone
receives their first injection (a.k.a. “induction”) requires
an opioid-free state several days prior to initiation, and
opioid withdrawal can be difficult to complete even in
inpatient settings with supportive medication [21]. In
contrast, buprenorphine induction does not require complete abstinence from opioids; first dose of buprenorphine may be administered 12–24 h after last use of
opioids. Multi-site trials in North America and Europe
noted that some individuals randomized to XR-NTX did
not complete induction; induction rates were enhanced
in inpatient settings (75%–90%) compared to primarily
outpatient settings (68%) [19, 22–24].
A 51-patient pilot study demonstrated the feasibility of
XR-NTX for the treatment of opioid and alcohol use disorders in two HIV primary care clinics [22]. Mean days
of opioid use in the past 30 days decreased in both the
treatment as usual group (i.e., methadone or buprenorphine) (17.3 to 4.1 days) and the XR-NTX group (20.3
to 7.7 days). HIV suppression increased from 67 to 80%
for XR-NTX and 58% to 75% for treatment as usual [22].
However, only 42% of participants with OUD assigned
to XR-NTX completed induction [22]. Based on these
pilot data, the “Comparing Treatments for HIV-Infected
Opioid Users in an Integrated Care Effectiveness Study
(CHOICES) Scale-up study” (CTN-0067) was redesigned
and expanded to five HIV clinics willing to randomize
patients to either opioid agonist therapy or opioid antagonist therapy. Of 55 participants randomized to XRNTX, 26 completed an XR-NTX induction.
Methods

We contacted 37 of the 55 participants randomized to
XR-NTX to conduct semi-structured, in-depth interviews (20 induced, 17 not induced) from five participating HIV clinics between 2018 and 2019, during early
study implementation. Study participants were selected
because they completed or did not complete a first
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XR-NTX injection, and the interview guides and analysis
were designed to assess how the experiences differed. The
semi-structured research guides were created by the core
qualitative research team. We used a convenience sampling approach (based on participant and clinic scheduling availability) and all participants approached for the
interview agreed to participate. Qualitative interviews
assessed the opioid withdrawal and XR-NTX induction
experience for participants randomized to XR-NTX to
identify more effective strategies for initiating opioid
antagonist therapy. For those who did not initiate XRNTX, study participants were interviewed about their
induction attempt experience. Interviews were digitally
recorded, professionally transcribed, and examined using
thematic analysis [25].
Participant eligibility

Individuals with moderate or severe OUD and an HIV
viral RNA level of ≥ 200 copies/ml were eligible for the
CHOICES Scale Up Study. Participants randomized to
XR-NTX were eligible for qualitative interviews and
recruited during their scheduled clinic appointments
for MOUD, HIV care, or study visits. Potential interview
participants were informed of the overall aims of the
qualitative study and invited to participate in either faceto-face or telephone interviews. All individuals invited to
complete interviews agreed to participate. Participants
received a $50 gift card for their participation. The study’s
Central IRB reviewed the interview guides and approved
an information sheet for study participants [26].
Interviews

The semi-structured research guide was created by
the core qualitative research team; core research questions were asked but the interview allowed for followup probes by the investigator based on answers to the
original question. Two highly experienced qualitative
interviewers (KH and RB), who were not responsible for
enrolling participants in the clinical trial, conducted the
interviews. Face-to-face interviews (n = 19) were conducted in a private clinic room with only the interviewer
and the participant present. In the case of telephone
interviews (n = 18), study staff facilitated the initiation
of the call and then left the room so that the conversation between the interviewer and respondent was private. Interviews lasted between 20 and 40 min, averaged
33 min, and were digitally recorded. Interview topics
included: (1) participant characteristics, (2) current and
prior HIV care, (3) history of alcohol and drug use, (4)
substance use treatment history, (5) social supports, and
(6) views on medications for OUD including withdrawal
and induction experiences. Interviews were completed,
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recorded and professionally transcribed between July
2018 and November 2019.

Table 1 Participant characteristics

Analysis

Age

n

Mean Age

51 years old

Given the research aim to elicit how respondents constructed their own lived experience, a Constructivist
paradigm [27] was used. Within that paradigm, the team
followed Braun and Clarke’s [25] Thematic Analysis (TA)
as a specific approach to analysis. When applying TA, the
six-step procedures defined by Braun and Clarke were
applied. Themes were identified which related to opioid withdrawal and XR-NTX induction experiences and
barriers to induction using an inductive approach at the
semantic level. Three PhD level investigators (KH, RB,
DM) with extensive experience in qualitative data collection, analysis and publication [21, 28–31] drafted a list of
preliminary themes after reading interview transcripts
and two coded transcript themes (KH, RB). An intercoder reliability process assessed coding discrepancies
and a third coder (DM) adjudicated the coding [32]. Ten
percent of the transcripts were double-coded to achieve
an inter-coder reliability rate of 85%. After achieving
agreement on the themes, representative quotations were
selected by consensus. Atlas.ti 8 software facilitated data
processing and quotation retrieval.

Results
Participants included women (43%), African Americans (62%) and Hispanics (16%), between 27 to 69 years
of age (see Table 1). Twenty participants who had completed XR-NTX induction reported (1) readiness for
change, (2) a supportive environment during withdrawal
including comfort medications, and (3) caring interactions with staff. Four contrasting themes emerged among
participants (n = 17) who did not complete induction:
(1) concern and anxiety about withdrawal including past
negative experiences, (2) ambivalence about stopping
opioids, (3) concerns about XR-NTX effects, and (4)
preferences for other medications.
Themes associated with successful XR‑NTX induction
Readiness for change

For respondents who successfully completed induction,
the most common theme which emerged was around
their readiness to undergo induction. Before persons
with OUD begin treatment with XR-NTX, they must
be opioid-free prior to the first injection. If opioids are
present, the XR-NTX will displace the opioids from
their receptors and produce symptoms of opioid withdrawal, a constellation of uncomfortable, often severe,
flu-like symptoms. All CHOICES study participants
reported common opioid withdrawal symptoms such as
pain, diarrhea, nausea, headaches, and backaches. Given

N = 37
%

27–39

7

19

40–59

23

62

60–69

7

19

Men

21

57

Women

16

43

White

8

22

African American or Black

23

62

Hispanic

6

16

Less than High School graduate

18

48

High School graduate or GED

8

22

Some college

8

22

Associates degree

1

3

Bachelor’s degree

2

5

Gender

Race

Education

Marital status
Married/life partner

2

5

Divorced

8

22

Never married

21

57

Separated

4

11

Widowed

2

5

Employed

4

11

Unemployed or looking for work

19

51

Disabled

10

27

Retired

4

11

Employment status

the discomfort of opioid withdrawal, participants were
asked to talk about their motivation for induction onto
XR-NTX. Participants spoke of their families, a desire to
improve their lives, and being tired of life on opioids:
I think the will. Yes. Yes. … My wife, my children. I
have grown-up kids and I don’t want them to continue seeing me like this. … My wife has always
stayed with me… She has always been there with
me.[Case ID 32]
I just told myself ‘I wanted a better life’. [Case ID 19]
I’m really actually– I’m tired of getting– I’m tired… I
tell you I am tired. [Case ID 27]
Another related how their experience with overdose
and fear of dying provided motivation for induction onto
XR-NTX:
I OD’ed. Yeah. And I never overdosed on any substance before and every day I had to build up my
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mind, my body and my spirit to not use. It was a
hard thing to do. It was a struggle; my body is craving something and me saying no because I could die.
It was very hard but I did it. [Case ID 24]
One respondent recognized that study incentives
helped him complete the painful process of withdrawal
and gave him a sense that participation in the study was
beneficial.
The study was a way to get extra money and based
on the information they gave me about the risk and
what they were trying to accomplish I felt like I could
do it and … it was a worthwhile endeavor for me.
[Case ID 25]
Similar themes related to motivation to change were
echoed in advice that participants had for others who
were considering XR-NTX. Participants stressed the
importance of readiness and individual commitment to
stop opioid use and the importance of wanting to stop
opioid use.
Just make sure that you really want to stop using
because it do work. You have to be ready to stop
using and so be ready. Some be ready and they be
scared but it works. They don’t need to be scared but
just give yourself a chance. [Case ID 18]
I think other people who want to get clean, it’s going
to work perfectly. For other people who are doing it
for the wrong reasons, I think it’s going to keep them
from getting high but it’s not going to stop them from
wanting to use. The will has to be there. The body
will follow. [Case ID 30]
A supportive environment during withdrawal
including comfort medications

Another commonly discussed theme included discussion about the environment in which the respondents
underwent withdrawal. Participants completed opioid
withdrawal in inpatient facilities for medically managed
withdrawal, jails, at home, and on the streets with varying levels of comfort and success. Many participants had
difficulty accessing inpatient medically supervised withdrawal due to long waiting lists. While some participants
withdrew from opioids successfully at home, others
reported that home was a suboptimal location due to
ongoing availability of opioids or concerns about safety.
[If I tried to] withdraw at home, I would end up
using. I made up my mind to go on the treatment
because I really wanted the injection [XR-NTX].
[Case ID 33]
Prior to getting the shot [XR-NTX], I tried to detox
because I didn’t want to go into [inpatient] detox.
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I lasted about maybe a week or two, and that was
on the streets. That was hell, because everywhere
around me, everyone was using. [Case ID 30]
A respondent who completed withdrawal at home
mentioned that their friends in recovery checked on
them regularly throughout the process. They observed
that they would have been more comfortable in an inpatient facility if that had been an option. Although their
brothers and sisters checked on them regularly, for example, this participant would have preferred admission to
an inpatient facility for withdrawal management.
You need to be like somewhere where they can monitor your vitals. You can’t do it by yourself. I had my
apartment. They were there with me for the seventytwo hours but you need someone in case your body
just stops and you can’t do it alone. All my brothers
and sisters are in recovery now and they were calling
and coming back. [Case ID 24]
Participants who used medically managed withdrawal
facilities attributed their success to access to ancillary
medications and a supportive environment.
You know, you can relax and rest. You get the rest
you need and just focus on you. And then you have
medical assistance with problems or struggles or
anything like that or if you feel like crap you don’t
go, you know, and look to use. You just, you know,
get the help that you need to get through the medical
stuff. [Case ID 20]
Caring interactions with others

Though less commonly cited, a final theme among the
inducted participants was the critical role of supportive
study staff in helping them complete opioid withdrawal
and XR-NTX induction. Participants commented that
study staff provided both educational, operational, and
emotional support. These supports included information,
flexibility to accommodate life responsibilities such as
child care, and medications that helped to alleviate withdrawal symptoms.
Well, yes, yes, they did treat me well here, truly, they
treated me like I was family. I would come here with
my daughter because my wife couldn’t look after
her. So, sometimes, I had to take care of my daughter. Here, they took care of her while I was being seen
and all, they have treated me very well here. [Case
ID 32]
They did everything–awesome. Very awesome and
very, you know, good at explaining everything and
good at getting through all the paperwork. [Case ID
26]
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My doctor—my psychiatrist gave me the pills for
when I get sick, like stomach cramps, runny nose,
something for my, you know, the bones when I be
aching and stuff like that, she gave me medication
for all that. [Case ID 02]
Emotional support included compassion, encouragement, and helping participants cope with fears and
anxieties.
I don’t like needles at all so I had to mentally get
ready for that. So when Dr. (name) was there to do
the shot, okay, the lady (nurse) was like I am going
to hold your hand like this. Okay, ready. Go. And
he just like, was already done. Already put it in and
took it out and I’m still holding her hand waiting. I
didn’t even feel anything.” [Case ID 26]
My caseworker and [study staff helped] because they
talked with me and I wanted to prove to them that I
could do right. They let me know that there is somebody in this world that wants to see you get right.
And this … made me realize that some people in this
world will help you. [Case ID 19]
Themes associated with unsuccessful XR‑NTX induction

Study participants who were unable to complete induction emphasized fear of withdrawal, ambivalence about
stopping drug use, misperceptions of XR-NTX and a
preference for opioid agonist therapy.
Concern and anxiety about withdrawal
including past negative experiences

The most commonly discussed theme which emerged
concerned worry about withdrawal. Among individuals randomized to XR-NTX, fear of completing opioid
withdrawal was a common barrier to induction. They
described the physical and emotional symptoms associated with previous opioid withdrawal, including generalized pain, nausea, vomiting, diaphoresis and severe
anxiety. A 27-year-old woman reported:
I was really excited to get it and everything. That’s
what I wanted, was the [XR-NTX], but every time I
make a plan to go into detox, right there I am ready
and everything and then I can’t do it and back out.
They come and pick me up and I’m in the car and…I
have really, really bad anxiety. So it’s tense… It’s just
the fear of everything. [Case ID 11]
A middle-aged respondent experiencing homelessness
expressed that his inability to stop all opioids for more
than a day had to do with being homeless and lacking a
structured environment. He reported attempting to withdraw on his own to prepare for induction: “I tried to detox
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but it wouldn’t happen for me.” [Case ID 16]. He was unaware of any medically supervised withdrawal centers in
the area.
Some participants believed that transitioning directly
from heroin or fentanyl was extremely difficult or impossible. A 40-year-old man explained that he attempted
going through withdrawal for the XR-NTX injection
“three or four times” at home. He contemplated:
I know people take the shot but how do they get
clean by taking it, you know what I mean? I think
you all should have a way for them to methadone
down, then detox off methadone, then probably take
the shot. But that straight coming from heroin to the
shot, that’s the hard stuff. Cold turkey. That’s why
some people still out there now. They tried it, it don’t
work. [Case ID 06]
He had been injecting heroin for 22 years and reported
“buying methadone off the street” to taper off of heroin
in preparation for his XR-NTX induction, but ended up
enrolling in a methadone program instead:
[The study staff said] All right but you got to be
totally clean, you can’t take any methadone or have
none of that stuff in your system, nothing. It’s got to
be like cold. And especially injecting, my withdrawals are more extreme than I think the ones who
snorted. So I tried it. I tried it about two or three
times but you can’t take nothing with opioids in it.
Nothing to calm down your pain. It wasn’t working
at all. Wasn’t working at all. So I just started methadone. So it’s been hard but now I’m on the methadone program and I ain’t used in about a month and
a half so it’s been good. [Case ID 06]
A female respondent reported she “had once tried to
commit suicide because I wanted to stop using so bad.”
[Case ID 17] After 7 days of medically supervised withdrawal, however, a naloxone challenge precipitated
withdrawal.
I want the cravings to go away and that’s what the
[XR-NTX] shot should do. I went through detox
for seven days when I was doing the study, trying
to get on the … shot but fentanyl was in my system before I went in the detox and even after seven
days, after finishing the detox, fentantyl was still
in my system so I wasn’t able to get the shot. They
gave me the [naloxone] to try to take it out of there
but it instantly made me sick and I didn’t want to
do another dose of [naloxone] because it made me so
sick and then I went out and got me a bag of heroin
that day. It made me go through withdrawals really
bad, really quick. I was ready to leave instantly after
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that. [Case ID 17]
As a result, she began a methadone program and, at the
time of the interview, was still using some heroin to help
with cravings. Her ultimate goal was to complete withdrawal from opioids so that she can begin treatment with
XR-NTX:
I have an appointment with my counselor next
Wednesday to talk about me starting to decrease
from the methadone so that I can get down so they
can switch me to the [buprenorphine] again and
then she can switch me to the [XR-NTX] shot. [Case
ID 17]
Ambivalence about or reluctance to stop opioids

Ambivalence about stopping opioid use was common
among participants and some identified the positive
effects of opioid use that they would lose on XR-NTX.
The potential negative effects of XR-NTX were also of
concern. Participants feared, for example, that either they
would have pain and be unable to manage it without opioids, or they felt that opioids helped them cope with difficult life experiences. Others were simply not ready to
stop. Two participants summarized their feelings:
I don’t want to stop yet and get this twenty day
blocker. It’s definitely great for somebody who really
wants to stop and doesn’t have reservations. [Case
ID 10]
I’m not ready to get off heroin. I’m being honest.
[Case ID 09]
A respondent felt that opioids helped him maintain
employment by keeping him “well”. He was providing
financial support to his brother and therefore prioritized
his work over treatment:
Like when I am working, I just keep myself well….Some
of my family tells me you know, it’s better that you just go
into treatment for a while, get yourself together and then
things will probably fall into place and get better. Which
is true but by me just losing my mom a few months ago
mentally I tell myself I need to just work so I can help my
brother. [Case ID 03] One respondent discussed the complexities of avoiding withdrawal and how that related to
his feelings about treatment with XR-NTX:
For me, because me being used to getting high for so
long over twenty-seven years, it’s going to be hard…
I think I need to be on some medication that would
get me close to that standard than to just do cold
turkey. That’s still cold turkey to me—when you don’t
get high period, when you are used to getting high. So
it’s still a problem and I don’t want it to be a problem. Mentally.” [Case ID 15]
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Similarly, a 55 year old man talked about continuing to use heroin: “Cause I been doing it a long time
I probably would have had to do some more even if
I did take the shot.” [Case ID 16] When asked if he
would prefer to continue to use heroin, he divulged,
“For the moment, I am still using but I am really
thinking about trying to get off….I thought I felt
ready but I guess I am not, yet. [Case ID 16].
A 30-year-old respondent who did manual labor for a
living described how the positive effects of using heroin,
such as pain relief, outweighed the negative experiences
like withdrawal and other possible consequences.
No, [I am not ready to stop]. … I don’t know, it’s
weird, I want to but I don’t. When I stop, like I have
physical problems and when I’m high I don’t have
no aches, no pains, just when I’m like not actually
high, just living that lifestyle, I don’t have any pain
unless I just wake up in the morning and I am just
feeling a little sick. That’s the only thing but when I
get clean I have aches and pains and that’s-- it sucks.
… I don’t know, I just don’t know, I got to see. I have
been dodging bullets I’d say but you know, I just need
to bite the bullet and go see doctors and psychiatrists
you know, but…[Case ID 10]

Concerns about XR‑NTX effects

Some patients expressed negative perceptions about
XR-NTX including fear of experiencing opioid withdrawal, concerns about unmanaged pain, and the fact
that it is not an opioid agonist. In addition, participants
had previously received negative or potentially confusing information about the extended-release formulation
and were concerned that they would still have cravings,
try to use higher amounts of opioids and increase the
risk of overdose, or potentially increase use of stimulants
when they were unable to use opioids. When asked about
his perception of XR-NTX, a 36 year old Hispanic male
reported:
Maybe it has to do with that it was females that
were giving the [negative] feedback, just the females
acted that way so, anyway, the females that told me
about it, one of them told me that she was still sick
after taking a shot of [XR-NTX]. The other one told
me she turned into a crack addict-- a crack monster.
[Case ID 10]
When asked what she had heard about XR-NTX, a
female respondent reported that she had heard it was
“a good thing but don’t you never do the dope because
it’s going to kill you. Be ready you know in your heart you
won’t do it no more”. [Case ID 01].
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Preferences for other medications

Though less commonly cited, a few participants assigned
to XR-NTX preferred opioid agonist therapy with
buprenorphine or methadone, particularly when they had
prior beneficial experiences with either medication. In
some cases, participants were exposed to buprenorphine
or methadone during medically supervised withdrawal
admissions and opted to remain on those medications
even though they had been randomized to XR-NTX.
A male participant reported that after study staff found
him an inpatient medically supervised withdrawal center,
he was still testing positive for opioids. He was subsequently moved to a hospital, where he was provided
buprenorphine.
So, the next step from the detox was the inpatient
treatment at [name] … and I was there for four
months … Did good while I was there. I stayed clean.
I was introduced to the [buprenorphine] and it was
working for me. I’m still using it. It’s still working for
me. [Case ID 12]
In collaboration with his HIV provider, he decided it
was best for him to remain on buprenorphine rather than
initiate XR-NTX. Another individual reported a similar
scenario; after being introduced to buprenorphine during
his medically supervised withdrawal, he mulled over the
decision about whether to switch to XR-NTX:
Well, when I heard, you know, at first I was going to
switch over and then something just said, no, no, no.
Stay with what you are doing because it’s working.
So, I stayed on the [buprenorphine]. I was satisfied.
[Case ID 13]

Discussion
The current study suggests that individuals who completed XR-NTX induction reported (1) readiness for
change, (2) a supportive environment during withdrawal
including comfort medications, and (3) caring interactions with staff. Four contrasting themes emerged among
participants (n = 17) who did not complete induction:
(1) concern and anxiety about withdrawal including past
negative experiences, (2) ambivalence about or reluctance
to stop opioids, (3) concerns about XR-NTX effects,
and (4) preferences for other medications. Of note, participants who experienced inpatient medically managed
withdrawal seemed to have an advantage over those who
did not have access. Inpatient treatment served the purpose of avoiding hazards associated with withdrawal and
return to use; in this environment, supportive medications can make the early hours and days of withdrawal as
comfortable as possible while removing the patient from
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their use environment. This is consistent with other studies showing that linking patients from inpatient managed
withdrawal programs to long‐term long term MOUD
treatment reduces illicit opioid use and increases days
of treatment [33, 34]. To our knowledge, this is the first
qualitative report of patients experiences with successful, and unsuccessful XR-NTX induction and advances
understanding of how to better support patients in initiation of XR-NTX. The paper’s contribution to the literature is that it documents study participants’ experiences
who tried but were unable to withdraw from opioids and
did not receive an injection of extended-release naltrexone. Patients who completed induction also reported
difficulty withdrawing but had sufficient social and environmental support to overcome withdrawal symptoms
and receive the first injection of XR-NTX.
The theme of motivation, or “readiness to change”, also
played an important role and is a well-known predictor
of treatment engagement [35]. Clinician assessment of
a patient’s motivation and use of techniques to advance
progression along stages of readiness such as Motivational Interviewing may be helpful.
Patient preference also influenced participant enthusiasm for treatment initiation, with some participants
indicating that their preference for opioid agonist treatment dampened their enthusiasm for XR-NTX induction. Patient preference was similarly associated with
treatment outcome in a large comparative effectiveness
trial of XR-NTX versus buprenorphine [19]. National
treatment guidelines endorse shared decision-making
in choosing medications for OUD [36]. Development
of patient-facing decision aids, as developed for other
medical treatments, may enhance patient-centered,
informed decision-making in choice of OUD treatment [37]. Our results are also consistent with another
recent investigation which found that it is more difficult
to induct patients onto XR-NTX than buprenorphine,
though requirements for a negative-buprenorphine
urine sample before XR-NTX induction may have exacerbated the underlying withdrawal tolerance issues [19].
Additionally, in a previous study of CHOICES study
staff, Hoffman et al. [21] found that a specific medication-related barrier to induction was patient fear of
opioid abstinence required prior to XR-NTX induction.
Similar results have been found in other studies of individuals using stimulants and opioids [31]. Overcoming
these barriers to XR-NTX induction may require additional counseling on how XR-NTX works, expectations
for induction, aggressive advance treatment of opioid
withdrawal symptoms (e.g., standing doses of clonidine,
trazodone for sleep, hydroxyzine for anxiety, etc.), and
respect for patient preferences for opioid agonist versus antagonist treatment. Study participants perceived
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that withdrawal from fentanyl was more difficult than
other opioids and a subsequent quantitative analysis
confirmed that induction rates were substantially lower
among individuals with fentanyl positive urine screens
(adjusted hazard ratio = 0.09, 95% confidence interval
0.03 to 0.24) [38]. This study points to the need for new
clinical interventions to manage fentanyl withdrawal.
Some limitations of the study should be acknowledged. It is important to note that this study was exploratory and assessed barriers and facilitators to XR-NTX
induction among a convenience sample of individuals
already enrolled in a treatment trial. It did not include
all patients in the trial, and thus may not represent all
views. Another limitation concerns the generalizability of the findings. The relatively small sample of individuals enrolled in a trial and receiving compensation
may not reflect the general population of those seeking
treatment for opioid use disorder. Additionally, there
was heterogeneity of sample demographics, interview
method (in-person, telephone), and induction settings.

Conclusions
The results highlight areas that need to be addressed in
order to improve uptake of XR-NTX. In the U.S., new
policies and guidelines are increasingly proposed and
adopted to address the opioid epidemic but more is
needed to reach high-needs populations, such as those
living with uncontrolled HIV disease [20]. Successful
induction onto XR-NTX can be associated with a supportive and safe setting for withdrawal management,
use of ancillary medication to minimize opioid withdrawal symptoms, and support from staff, family and
friends. Shared decision making that prioritizes patient
preferences helps patients better understand the effects
of opioid agonist and opioid antagonist therapies may
improve initiation of medications for opioid use disorder treatment.
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